secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001654954-24-008062
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial
--------------------------------------------------------------------------------

- Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
- Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.
- Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.
- BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.
- Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/0001654954-24-008062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-008062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer